Literature DB >> 24917419

Malignant melanoma: factors affecting the surgical interval from excision biopsy to definitive surgical management.

M R Boland1, R S Prichard, G A Bass, Z Al-Hilli, A Levendale, D Gibbons, K Sheahan, B Kirby, E W McDermott, D Evoy.   

Abstract

INTRODUCTION: Surgery remains the mainstay of treatment for malignant melanoma. Despite previous studies examining the surgical interval (SI) between the diagnostic excision biopsy (DEB) and definitive surgical management there remains few guidelines regarding an optimal time interval. The aim of this study was to determine the SI between DEB and definitive surgery and elucidate factors associated with delays in management of malignant melanoma.
METHODS: A retrospective study of 107 consecutive patients who had a DEB and subsequent wide local excision between January 2011 and June 2012 was performed. Mode of referral and dates of diagnostic biopsy/definitive surgery were documented. Patient demographics and tumour characteristics were reviewed.
RESULTS: The mean age was 59.6 years, and male:female ratio was 1:1.3. Median duration of the SI was 41 ± 27 days (range 6-137 days). The SI was increased when dermatologists performed the DEB as opposed to general surgeons (p = 0.035). The anatomic location of the lesion predicted the SI, with lesions of the head/neck undergoing definitive excision 48 ± 32.3 days after DEB vs. 37.5 ± 22.6 days for all other sites (p = 0.001). Neither demographic factors nor histopathological prognostic features affected the SI. Reasons for a prolonged SI included referrals to different services and time for pre-operative planning.
CONCLUSIONS: Significant variations were noted in the SI predominantly accounted for by mode of referral and location of the malignant melanoma. Further investigation is required to elucidate factors affecting the SI and its subsequent effect on patient outcomes.

Entities:  

Mesh:

Year:  2014        PMID: 24917419     DOI: 10.1007/s11845-014-1157-5

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  12 in total

1.  A new American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; M B Atkins; N Cascinelli; D G Coit; I D Fleming; A Houghton; J M Kirkwood; M F Mihm; D L Morton; D Reintgen; M I Ross; A Sober; S J Soong; J A Thompson; J F Thompson; J E Gershenwald; K M McMasters
Journal:  Cancer       Date:  2000-03-15       Impact factor: 6.860

2.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

3.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

Authors:  Milena Sant; Claudia Allemani; Mariano Santaquilani; Arnold Knijn; Francesca Marchesi; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2009-01-24       Impact factor: 9.162

4.  Melanoma, version 2.2013: featured updates to the NCCN guidelines.

Authors:  Daniel G Coit; Robert Andtbacka; Christopher J Anker; Christopher K Bichakjian; William E Carson; Adil Daud; Dominick Dimaio; Martin D Fleming; Valerie Guild; Allan C Halpern; F Stephen Hodi; Mark C Kelley; Nikhil I Khushalani; Ragini R Kudchadkar; Julie R Lange; Anne Lind; Mary C Martini; Anthony J Olszanski; Scott K Pruitt; Merrick I Ross; Susan M Swetter; Kenneth K Tanabe; John A Thompson; Vijay Trisal; Marshall M Urist; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-04-01       Impact factor: 11.908

5.  The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival.

Authors:  D B McKenna; R J Lee; R J Prescott; V R Doherty
Journal:  Br J Dermatol       Date:  2002-07       Impact factor: 9.302

6.  Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome?

Authors:  Susanne Carpenter; Barbara Pockaj; Amylou Dueck; Richard Gray; David Kurtz; Aleksander Sekulic; William Casey
Journal:  Am J Surg       Date:  2008-12       Impact factor: 2.565

7.  A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma.

Authors:  D B McKenna; J C Marioni; R J Lee; R J Prescott; V R Doherty
Journal:  Br J Dermatol       Date:  2004-09       Impact factor: 9.302

8.  The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma.

Authors:  J W Kelly; R W Sagebiel; W Calderon; L Murillo; R L Dakin; M S Blois
Journal:  Ann Surg       Date:  1984-12       Impact factor: 12.969

9.  Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.

Authors:  Claus Garbe; Ketty Peris; Axel Hauschild; Philippe Saiag; Mark Middleton; Alan Spatz; Jean-Jacques Grob; Josep Malvehy; Julia Newton-Bishop; Alexander Stratigos; Hubert Pehamberger; Alexander M Eggermont
Journal:  Eur J Cancer       Date:  2012-09-13       Impact factor: 9.162

10.  The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival.

Authors:  Brian M Parrett; Neil A Accortt; Rui Li; Amarjit S Dosanjh; Suresh Thummala; Raj Kullar; James E Cleaver; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

View more
  1 in total

1.  University Hospital Waterford: 5-year experience of cutaneous melanoma.

Authors:  R Sehgal; C X Cheung; R Alradadi; D A Healy; R Landers; G T O'Donoghue
Journal:  Ir J Med Sci       Date:  2016-11-21       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.